JP2022547313A5 - - Google Patents

Info

Publication number
JP2022547313A5
JP2022547313A5 JP2022515906A JP2022515906A JP2022547313A5 JP 2022547313 A5 JP2022547313 A5 JP 2022547313A5 JP 2022515906 A JP2022515906 A JP 2022515906A JP 2022515906 A JP2022515906 A JP 2022515906A JP 2022547313 A5 JP2022547313 A5 JP 2022547313A5
Authority
JP
Japan
Prior art keywords
hcmv
sequence
immunogenic composition
seq
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022515906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547313A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050392 external-priority patent/WO2021050864A1/en
Publication of JP2022547313A publication Critical patent/JP2022547313A/ja
Publication of JP2022547313A5 publication Critical patent/JP2022547313A5/ja
Withdrawn legal-status Critical Current

Links

JP2022515906A 2019-09-11 2020-09-11 ヒトサイトメガロウイルスワクチン Withdrawn JP2022547313A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962899129P 2019-09-11 2019-09-11
US62/899,129 2019-09-11
US201962899624P 2019-09-12 2019-09-12
US62/899,624 2019-09-12
US202062958623P 2020-01-08 2020-01-08
US62/958,623 2020-01-08
PCT/US2020/050392 WO2021050864A1 (en) 2019-09-11 2020-09-11 Human cytomegalovirus vaccine

Publications (2)

Publication Number Publication Date
JP2022547313A JP2022547313A (ja) 2022-11-11
JP2022547313A5 true JP2022547313A5 (enExample) 2023-09-20

Family

ID=74867306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515906A Withdrawn JP2022547313A (ja) 2019-09-11 2020-09-11 ヒトサイトメガロウイルスワクチン

Country Status (6)

Country Link
US (1) US20220347292A1 (enExample)
EP (1) EP4028030A4 (enExample)
JP (1) JP2022547313A (enExample)
AU (1) AU2020346041A1 (enExample)
CA (1) CA3154082A1 (enExample)
WO (1) WO2021050864A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2016341309A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Cancer vaccines
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
WO2017070601A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (vzv)
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
CA3036831A1 (en) 2016-09-14 2018-03-22 Modernatx, Inc. High purity rna compositions and methods for preparation thereof
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
US11384352B2 (en) 2016-12-13 2022-07-12 Modernatx, Inc. RNA affinity purification
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. RESPIRATORY SYNCYTIAL VIRUS Vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MA49914A (fr) 2017-08-18 2021-04-21 Modernatx Inc Procédés analytiques par hplc
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
EP3675817A1 (en) 2017-08-31 2020-07-08 Modernatx, Inc. Methods of making lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. RNA VACCINES AGAINST ZIKA VIRUS
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
AU2020224103A1 (en) 2019-02-20 2021-09-16 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
IL297419B2 (en) 2020-04-22 2025-02-01 BioNTech SE Coronavirus vaccine
CA3193042A1 (en) * 2020-08-25 2022-03-03 Modernatx, Inc. Human cytomegalovirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
CN115611757A (zh) * 2021-07-16 2023-01-17 江苏慧聚药业股份有限公司 mRNA传递剂的合成
CN115703713B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023212696A1 (en) 2022-04-29 2023-11-02 Modernatx, Inc. Lyophilized human cytomegalovirus vaccines
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3528821A4 (en) * 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE

Similar Documents

Publication Publication Date Title
JP2022547313A5 (enExample)
CN114081943B (zh) 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用
EP4628510A1 (en) Multi-antigen chimeric poxvirus vaccine and use thereof
CN114854772B (zh) 水痘-带状疱疹病毒mRNA疫苗及其制备方法和应用
KR20050002868A (ko) 인간 파필로마 바이러스의 바이러스 유사 입자
Tron et al. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences
CN110996999A (zh) 包含插入有脂肽的脂质体作为有效成分的疫苗佐剂及其用途
JP2002512026A5 (enExample)
CN116036259A (zh) 猴痘病毒多抗原mRNA疫苗及其应用
CN115820696A (zh) 治疗性多价HPV mRNA疫苗及其制备方法
Cortesi et al. Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes
CN113226364A (zh) 组合物和方法
US20250339511A1 (en) Nucleic acid vaccine against monkeypox virus and use thereof
CN114277039B (zh) 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
WO2024188144A1 (zh) 痘病毒mRNA疫苗及用途
CN109219449B (zh) 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物
WO2024055273A1 (zh) 一种狂犬病mRNA疫苗、其制备及应用
WO2024041612A1 (zh) 一种正痘病毒属mRNA疫苗及其制备方法和用途
CN116410992A (zh) 预防和/或治疗新型冠状病毒的mRNA、疫苗及其制备方法和应用
CN120888568A (zh) 一种预防或治疗乙肝病毒感染的mRNA疫苗及其应用
CN120305396A (zh) 一种猴痘病毒抗原表位mRNA组合物及其应用
CN120202020A (zh) 工程化水痘带状疱疹病毒带状疱疹mRNA疫苗
AU2004281098B2 (en) Pharmaceutical compositions for therapeutic use
JP2002527527A (ja) 最小プロモーターおよびその使用
WO2025002352A1 (zh) 一种含有阳离子脂质的药物组合物及其用途